Saliva diagnostics: Salivaomics, saliva exosomics, and saliva liquid biopsy.
Saliva diagnostics
biomarker
liquid biopsy
saliva exosomics
salivaomics
Journal
Journal of the American Dental Association (1939)
ISSN: 1943-4723
Titre abrégé: J Am Dent Assoc
Pays: England
ID NLM: 7503060
Informations de publication
Date de publication:
08 2023
08 2023
Historique:
received:
30
01
2023
revised:
12
04
2023
accepted:
11
05
2023
medline:
31
7
2023
pubmed:
28
7
2023
entrez:
27
7
2023
Statut:
ppublish
Résumé
Each day, humans produce approximately 0.5 through 1.5 liters of saliva, a biofluid that is rich in biological omic constituents. Our lack of understanding how omic biomarkers migrate from diseased tissue to the saliva has impeded the clinical translation of saliva testing. Although such biomarkers must be conveyed via the vascular and lymphatic systems to the salivary glands, the molecular mechanisms that underlie this transport remain unclear. Although COVID-19 highlighted the need for rapid and reliable testing for infectious diseases, it represents only one of the many health conditions that potentially can be diagnosed using a saliva sample. The authors discuss salivaomics, saliva exosomics, and the mechanisms on which saliva diagnostics are based and introduce a novel electrochemical sensing technology that may be exploited for saliva liquid biopsy. The utility of saliva for screening for lung cancer is under investigation. Saliva testing may be used to stratify patients, monitor treatment response, and detect disease recurrence. The authors also highlight the landscapes of saliva-based SARS-CoV-2 testing and ultrashort cell-free DNA and outline how these fields are likely to evolve in the near future. Breakthroughs in the study of saliva research, therefore, will facilitate clinical deployment of saliva-based testing.
Sections du résumé
BACKGROUND
Each day, humans produce approximately 0.5 through 1.5 liters of saliva, a biofluid that is rich in biological omic constituents. Our lack of understanding how omic biomarkers migrate from diseased tissue to the saliva has impeded the clinical translation of saliva testing. Although such biomarkers must be conveyed via the vascular and lymphatic systems to the salivary glands, the molecular mechanisms that underlie this transport remain unclear. Although COVID-19 highlighted the need for rapid and reliable testing for infectious diseases, it represents only one of the many health conditions that potentially can be diagnosed using a saliva sample.
TYPES OF STUDIES REVIEWED
The authors discuss salivaomics, saliva exosomics, and the mechanisms on which saliva diagnostics are based and introduce a novel electrochemical sensing technology that may be exploited for saliva liquid biopsy.
RESULTS
The utility of saliva for screening for lung cancer is under investigation. Saliva testing may be used to stratify patients, monitor treatment response, and detect disease recurrence. The authors also highlight the landscapes of saliva-based SARS-CoV-2 testing and ultrashort cell-free DNA and outline how these fields are likely to evolve in the near future.
PRACTICAL IMPLICATIONS
Breakthroughs in the study of saliva research, therefore, will facilitate clinical deployment of saliva-based testing.
Identifiants
pubmed: 37500232
pii: S0002-8177(23)00280-5
doi: 10.1016/j.adaj.2023.05.006
pii:
doi:
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Review
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
696-704Subventions
Organisme : NCI NIH HHS
ID : UH3 CA206126
Pays : United States
Organisme : NIDCR NIH HHS
ID : R03 DE029272
Pays : United States
Organisme : NIDCR NIH HHS
ID : R03 DE027759
Pays : United States
Organisme : NCATS NIH HHS
ID : UG3 TR002978
Pays : United States
Organisme : NIDCR NIH HHS
ID : U01 DE017790
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA233370
Pays : United States
Informations de copyright
Copyright © 2023 American Dental Association. Published by Elsevier Inc. All rights reserved.